Julio Camarero

Prof. Julio Camarero

Professor of Pharmacology and Pharmaceutical Sciences, Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089-9121, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2012 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
PAPaul G. Arnison
Paul G. Arnison
MBMervyn J. Bibb
Mervyn J. Bibb
GBGabriele Bierbaum
Gabriele Bierbaum
ABAlbert A. Bowers
Albert A. Bowers
TBTim S. Bugni
Tim S. Bugni
WDWilfred A. van der Donk
Wilfred A. van der Donk
Covering: 1988 to 2012 This review presents recommended nomenclature for the biosynthesis of ribosomally synthesized and post-translationally modified peptides (RiPPs), a rapidly growing class of natural products. The current knowledge regarding the biosynthesis of the >20 distinct compound classes is also reviewed, and commonalities are discussed.

12 July 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YJYanbin Ji
Yanbin Ji
SMSubhabrata Majumder
Subhabrata Majumder
MMMelissa Millard
Melissa Millard
RBRadhika Borra
Radhika Borra
TBTao Bi
Tao Bi
Julio CamareroJulio Camarero
Julio Camarero

1 May 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DWDavid W. Wood
David W. Wood
Julio CamareroJulio Camarero
Julio Camarero
The discovery of inteins in the early 1990s opened the door to a wide variety of new technologies. Early engineered inteins from various sources allowed the development of self-cleaving affinity tags and new methods for joining protein segments through expressed protein ligation. Some applications were developed around native and engineered split inteins, which allow protein segments expressed separately to be spliced together in vitro. More recently, these early applications have been expanded and optimized through the discovery of highly efficient trans-splicing and trans-cleaving inteins. These new inteins have enabled a wide variety of applications in metabolic engineering, protein labeling, biomaterials construction, protein cyclization, and protein purification.

27 November 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TATeshome L. Aboye
Teshome L. Aboye
HHHelen Ha
Helen Ha
SMSubhabrata Majumder
Subhabrata Majumder
FCFrauke Christ
Frauke Christ
ZDZeger Debyser
Zeger Debyser
Julio CamareroJulio Camarero
Julio Camarero

30 November 2010 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
LBLuis Berrade
Luis Berrade
AGAngie E. Garcia
Angie E. Garcia
Julio CamareroJulio Camarero
Julio Camarero

1 December 2011 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
AGAndrew Gould
Andrew Gould
YJYanbin Ji
Yanbin Ji
TATeshome L. Aboye
Teshome L. Aboye
Julio CamareroJulio Camarero
Julio Camarero
Cyclotides are a unique and growing family of backbone cyclized peptides that also contain a cystine knot motif built from six conserved cysteine residues. This unique circular backbone topology and knotted arrangement of three disulfide bonds makes them exceptionally stable to thermal, chemical, and enzymatic degradation compared to other peptides of similar size. Aside from the conserved residues forming the cystine knot, cyclotides have been shown to have high variability in their sequences. Consisting of over 160 known members, cyclotides have many biological activities, ranging from anti-HIV, antimicrobial, hemolytic, and uterotonic capabilities; additionally, some cyclotides have been shown to have cell penetrating properties. Originally discovered and isolated from plants, cyclotides can also be produced synthetically and recombinantly. The high sequence variability, stability, and cell penetrating properties of cyclotides make them potential scaffolds to be used to graft known active peptides or engineer peptide-based drug design. The present review reports recent findings in the biological diversity and therapeutic potential of natural and engineered cyclotides.